<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382265</url>
  </required_header>
  <id_info>
    <org_study_id>RO1 DK71603</org_study_id>
    <secondary_id>U01DK096037</secondary_id>
    <secondary_id>U01DK071603</secondary_id>
    <secondary_id>U34DK090957</secondary_id>
    <nct_id>NCT00382265</nct_id>
  </id_info>
  <brief_title>Tamsulosin for Urolithiasis in the Emergency Dept</brief_title>
  <acronym>STONE</acronym>
  <official_title>Study of Tamsulosin for Urolithiasis in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Meltzer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urolithiasis is a disease that effects 12% of the population and its incidence is growing. In
      the US there are over 1.1 million visits annually to Emergency Departments for renal colic.
      The disease is extremely painful, often requiring large amounts of narcotic analgesia, and
      results in lost work days. Moreover, up to 30% of patients may eventually require lithotripsy
      or surgical removal of the stone. Currently there are no medical interventions other than
      analgesia which are offered to patients.

      Based on encouraging results from several small European clinical studies, the researchers
      hypothesize that the administration of tamsulosin to patients with symptomatic urolithiasis
      will enhance stone passage, and reduce both the time to recovery and the need for surgical
      intervention or lithotripsy. The researchers will conduct a study by identifying and
      recruiting patients presenting with urolithiasis in the emergency departments of four
      institutions.

      A total of 500 consenting subjects will be randomly assigned to one of two groups:

        1. tamsulosin for a maximum of 28 days;

        2. placebo for a maximum of 28 days.

      In addition, both groups will receive standard analgesic therapy.

      The study team, which will be blinded to treatment status, will monitor each subject's
      clinical progress and outcome. The primary objectives of this study are:

        1. to determine if tamsulosin is effective, and

        2. to evaluate the safety of the therapy.

      Another objective is to identify the most appropriate clinical subgroup(s) for treatment.

      If the therapeutic benefits observed in smaller clinical studies are replicated,
      administration of these medications should produce several benefits, including:

        1. a reduction in time to pain free recovery and hence a more rapid return to employment;

        2. decreased requirements for narcotic analgesia;

        3. less need for urological out-patient clinic follow-up;

        4. decreased need for surgical intervention or lithotripsy; and

        5. substantial cost savings.

      If this therapy is beneficial, it will represent a major advance in the treatment of
      urolithiasis. This objective is a major stated goal of the NIDDK (National Institute of
      Diabetes and Digestive and Kidney Diseases) Clinical Urology Program, which has a stated
      mission to improve the treatment of urolithiasis.

      Kidney stones are a major public health issue, and one person in eight will be affected by
      the disease. If the hypothesis is verified, the researchers will provide the first medical
      therapy ever for this disease. This therapy, if effective, will reduce the amount of time a
      patient is off work because of the pain from the disease, and may also reduce the need for
      expensive and time-consuming surgical treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">February 1, 2017</completion_date>
  <primary_completion_date type="Actual">February 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Passing Their Stone Within 28 Days by Self Report</measure>
    <time_frame>28 days</time_frame>
    <description>Hypothesis: The administration of tamsulosin after the clinical and radiographic diagnosis of acute urolithiasis will produce an increase in the proportion of patients passing their stone within 28 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any Pain Medication</measure>
    <time_frame>28 days</time_frame>
    <description>Patients on any pain medication at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Surgical Intervention</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crossover to Open Label Tamsulosin</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmation of Stone Passage on CT</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to Work (if Employed)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">512</enrollment>
  <condition>Ureterolithiases</condition>
  <arm_group>
    <arm_group_label>Tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamsulosin 0.4mg PO qd for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo PO qd for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamsulosin</intervention_name>
    <description>tamsulosin 0.4mg po qd for 28 days</description>
    <arm_group_label>Tamsulosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo po qd for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Evidence of ureterolithiasis (i.e. stone is located in ureter, not in bladder) as
             demonstrated on radiographic studies, specifically non-contrast spiral CT.

          3. Willingness to participate and able to proceed with standard outpatient management (no
             personal or job-related issues, e.g. airline pilot.

          4. Has a telephone in order to be contacted for follow-up.

        Exclusion Criteria:

          1. Patient desiring or requiring immediate surgical intervention making then not a
             candidate for outpatient kidney stone management.

          2. Current urinary tract infection based on urine dipstick as admission and urgent
             procedural management are likely indicated.

          3. Known anatomical genitourinary abnormalities or prior Genitourinary surgeries.

          4. Positive pregnancy test making proper radiological imaging contraindicated.

          5. Breastfeeding mothers.

          6. History of hypersensitivity to tamsulosin.

          7. Current use of alpha blockers or calcium channel blockers.

          8. Current use of steroids which may have an independent effect on stone expulsion.

          9. Spontaneous stone expulsion prior to enrollment.

         10. Largest stone dimension ≥ 9mm assessed using radiologic imaging, being very unlikely
             to pass spontaneously.

         11. Presence of stone in the bladder.

         12. Current use of vardenafil which is tamsulosin contraindicated.

         13. Ipsilateral, transplanted or solitary kidney as hospitalization may be necessary.

         14. Known renal insufficiency.

         15. Fever defined as &gt;101.5°F which may indicate infection.

         16. Floppy iris syndrome which is tamsulosin contraindicated.

         17. Planned cataract surgery in the next 60 days which is tamsulosin contraindicated.

         18. Prisoners /wards of state.

         19. Prior enrollment in STONE (Candidates who are screened and found ineligible may be
             rescreened at a later date.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew C Meltzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 28, 2006</study_first_submitted>
  <study_first_submitted_qc>September 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2006</study_first_posted>
  <results_first_submitted>May 1, 2018</results_first_submitted>
  <results_first_submitted_qc>November 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2018</results_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Andrew Meltzer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>urolithiasis</keyword>
  <keyword>renal colic</keyword>
  <keyword>kidney stones</keyword>
  <keyword>urinary stone disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 4, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT00382265/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Comparator:1</title>
          <description>Tamsulosin 0.4mg PO
tamsulosin: tamsulosin 0.4mg po qd for 28 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo Comparator:2</title>
          <description>Placebo
tamsulosin: tamsulosin 0.4mg po qd for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tamsulosin Group</title>
          <description>Tamsulosin 0.4mg PO
tamsulosin: tamsulosin 0.4mg po qd for 28 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Placebo for 28 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="267"/>
            <count group_id="B2" value="245"/>
            <count group_id="B3" value="512"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="13.6"/>
                    <measurement group_id="B2" value="39.3" spread="12.9"/>
                    <measurement group_id="B3" value="40.6" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-White Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Passing Their Stone Within 28 Days by Self Report</title>
        <description>Hypothesis: The administration of tamsulosin after the clinical and radiographic diagnosis of acute urolithiasis will produce an increase in the proportion of patients passing their stone within 28 days.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin</title>
            <description>Tamsulosin 0.4mg PO
tamsulosin: tamsulosin 0.4mg po qd for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
tamsulosin: tamsulosin 0.4mg po qd for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Passing Their Stone Within 28 Days by Self Report</title>
          <description>Hypothesis: The administration of tamsulosin after the clinical and radiographic diagnosis of acute urolithiasis will produce an increase in the proportion of patients passing their stone within 28 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Any Pain Medication</title>
        <description>Patients on any pain medication at day 28</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin</title>
            <description>Tamsulosin 0.4mg PO
tamsulosin: tamsulosin 0.4mg po qd for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill po qd for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Any Pain Medication</title>
          <description>Patients on any pain medication at day 28</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Surgical Intervention</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin</title>
            <description>Tamsulosin 0.4mg po qd for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Pill qd for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Surgical Intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crossover to Open Label Tamsulosin</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin</title>
            <description>Tamsulosin 0.4mg po qd for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pill po qd for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Crossover to Open Label Tamsulosin</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmation of Stone Passage on CT</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin</title>
            <description>Tamsulosin 0.4mg po qd for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Pill qd for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmation of Stone Passage on CT</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Return to Work (if Employed)</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tamsulosin</title>
            <description>Tamsulosin 0.4mg po qd for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Placebo pill po qd for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Return to Work (if Employed)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for 90 days after each patient enrollment in the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tamsulosin</title>
          <description>Tamsulosin 0.4mg po qd for 28 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo Pill po qd for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Meltzer, MD, MS</name_or_title>
      <organization>George Washington University</organization>
      <phone>202-741-2952</phone>
      <email>ameltzer@mfa.gwu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

